脓疱型银屑病诊疗中国专家共识（2022版）

doi:10.35541/cjd.20210698

Abstract

Abstract: 【Abstract】 Pustular psoriasis is a special type of psoriasis, characterized by aseptic pustules on an erythematous base. Its etiology involves multiple factors such as heredity, immunity and infection. Pustular psoriasis can be classified into 2 subtypes: localized and generalized pustular psoriasis. Localized pustular psoriasis is mainly managed with topical treatment, and patients with poor response to topical treatment can be treated with systemic therapy and phototherapy; generalized pustular psoriasis is usually treated with systemic therapy, which can be combined with topical treatment and phototherapy. Based on the latest Chinese and international guidelines and consensus, and combined with the current status of diagnosis and treatment of pustular psoriasis in China, the working group established this expert consensus, with an emphasis on clinical manifestations, classification, laboratory examinations, diagnostic criteria, and treatment of pustular psoriasis, so as to further develop a standardized model for diagnosis and treatment of pustular psoriasis.

Key words: Psoriasis, Diagnosis, Therapy, Pustular psoriasis, Expert consensus

Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022）[J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.doi:10.35541/cjd.20210698

References ［52］

［1］	全国银屑病流行调查组. 全国1984年银屑病流行调查报告［J］. 中华皮肤科杂志, 1986,19（5）:253⁃261.
［2］	Feng JN, Guo JZ, Zhang Q, et al. Epidemiology and disease burden of GPP in urban China from 2012 to 2016 and a systematic review［C/OL］//e⁃Poster at EADV 30th congress. 2021［2021⁃09⁃29］. https://www.eadvcongress2021.org/index.php/home/scientific/scientific⁃programme.
［3］	Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background［J］. Acta Derm Venereol, 1996,76（1）:68⁃71. doi: 10.2340/00015555766871.
［4］	Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis （Zumbusch）: a French epidemiological survey［J］. Eur J Dermatol. 2006,16（6）:669⁃673.
［5］	Ayala⁃Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases［J］. Psoriasis （Auckl）, 2016,6:7⁃32. doi: 10.2147/PTT.S64950.
［6］	Li X, Chen M, Fu X, et al. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris［J］. J Dermatol Sci, 2014,76（2）:132⁃138. doi: 10.1016/j.jdermsci.2014.08.007.
［7］	Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin⁃36 signalling in plaque psoriasis and pustular psoriasis［J］. Acta Derm Venereol, 2018,98（1）:5⁃13. doi: 10.2340/00015555⁃2808.
［8］	Körber A, Mössner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis［J］. J Invest Dermatol, 2013,133（11）:2634⁃2637. doi: 10.1038/jid.2013.214.
［9］	Qin P, Zhang Q, Chen M, et al. Variant analysis of CARD14 in a Chinese Han population with psoriasis vulgaris and generalized pustular psoriasis［J］. J Invest Dermatol. 2014,134（12）:2994⁃2996. doi: 10.1038/jid.2014.269.
［10］	Li L, You J, Fu X, et al. Variants of CARD14 are predisposing factors for generalized pustular psoriasis （GPP） with psoriasis vulgaris but not for GPP alone in a Chinese population［J］. Br J Dermatol, 2019,180（2）:425⁃426. doi: 10.1111/bjd.17392.
［11］	Fu F, Sun Y, Zhao Q, et al. Rare CARD14 missense variants associated with palmoplantar pustulosis （PPP） in the Chinese Han population［J］. Eur J Dermatol, 2019,29（1）:99⁃100. doi: 10.1684/ejd.2018.3457.
［12］	Johnston A, Xing X, Wolterink L, et al. IL⁃1 and IL⁃36 are dominant cytokines in generalized pustular psoriasis［J］. J Allergy Clin Immunol, 2017,140（1）:109⁃120. doi: 10.1016/j.jaci.2016.08.056.
［13］	Pfaff CM, Marquardt Y, Fietkau K, et al. The psoriasis⁃associated IL⁃17A induces and cooperates with IL⁃36 cytokines to control keratinocyte differentiation and function［J］. Sci Rep, 2017,7（1）:15631. doi: 10.1038/s41598⁃017⁃15892⁃7.
［14］	Arakawa A, Vollmer S, Besgen P, et al. Unopposed IL⁃36 activity promotes clonal CD4（+） T⁃cell responses with IL⁃17A production in generalized pustular psoriasis［J］. J Invest Dermatol, 2018,138（6）:1338⁃1347. doi: 10.1016/j.jid.2017.12. 024.
［15］	Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis ⁃ a model disease for specific targeted immunotherapy, systematic review［J］. Exp Dermatol, 2018,27（10）:1067⁃1077. doi: 10.1111/exd.13699.
［16］	Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism［J］. J Dermatol Sci, 2020,98（1）:13⁃19. doi: 10.1016/j.jdermsci.2020. 03.003.
［17］	Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1792⁃1799. doi: 10.1111/jdv. 14386.
［18］	秦万章，顾军. 银屑病学［M］. 南京: 江苏凤凰科学技术出版社, 2020.
［19］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018完整版）［J］. 中华皮肤科杂志, 2019,52（10）:667⁃710. doi: 10.35541/cjd.20190847.
［20］	Sugiura K, Nakasuka A, Kono H, et al. Impetigo herpetiformis with IL36RN mutations in a Chinese patient: a founder haplotype of c.115+6T>C in East Asia［J］. J Dermatol Sci, 2015,79（3）:319⁃320. doi: 10.1016/j.jdermsci.2015.06.003.
［21］	Sugiura K, Oiso N, Iinuma S, et al. IL36RN mutations underlie impetigo herpetiformis［J］. J Invest Dermatol, 2014,134（9）:2472⁃2474. doi: 10.1038/jid.2014.177.
［22］	Wang Q, Liu W, Zhang L. Clinical features of von Zumbusch type of generalized pustular psoriasis in children: a retrospective study of 26 patients in southwestern China［J］. An Bras Dermatol, 2017,92（3）:319⁃322. doi: 10.1590/abd1806⁃4841.20175536.
［23］	Owczarczyk⁃Saczonek A, Znajewska⁃Pander A, Owczarek W, et al. Clinicopathologic retrospective analysis of annular pustular psoriasis［J］. Acta Dermatovenerol Alp Pannonica Adriat, 2018,27（4）:215⁃219.
［24］	Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes［J］. J Allergy Clin Immunol, 2019,143（3）:1021⁃1026. doi: 10.1016/j.jaci.2018. 06.038.
［25］	Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases［J］. Arch Dermatol, 1991,127（9）:1339⁃45. PMID: 1892402.
［26］	Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP［J］. J Dermatol, 2018,45（11）:1235⁃1270. doi: 10.1111/1346⁃8138.14523.
［27］	Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2001,145（4）:546⁃553. doi: 10.1046/j.1365⁃2133.2001.04411.x.
［28］	Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation［J］. J Am Acad Dermatol, 2012,67（2）:279⁃288. doi: 10.1016/j.jaad.2011.01.032.
［29］	Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies［J］. Clin Rev Allergy Immunol, 2018,54（1）:102⁃113. doi: 10.1007/s12016⁃018⁃8668⁃1.
［30］	Rueda⁃Gotor J, González⁃Gay MA, Blanco Alonso R, et al. Successful effect of tocilizumab in anti⁃TNF⁃α⁃induced palmoplantar pustulosis in rheumatoid arthritis［J］. Joint Bone Spine, 2012,79（5）:510⁃513. doi: 10.1016/j.jbspin.2012.06.010.
［31］	Wilsmann⁃Theis D, Jacobi A, Frambach Y,et al. Palmoplantar pustulosis⁃ a cross⁃sectional analysis in Germany［J］. Dermatol Online J, 2017,23（4）:13030/qt0h15613d. doi: 10.5070/D32340 34627.
［32］	Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options［J］. Int J Dermatol, 2011,50（10）:1195⁃1211. doi: 10.1111/j.1365⁃4632.2011.04993.x.
［33］	Soleymani T, Vassantachart JM, Wu JJ. Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review［J］. J Drugs Dermatol, 2016,15（3）:293⁃301. PMID: 26954314.
［34］	Sheu JS, Divito SJ, Enamandram M, et al. Dapsone therapy for pustular psoriasis: case series and review of the literature［J］. Dermatology,2016,232（1）:97⁃101. doi: 10.1159/000431171.
［35］	Ji YZ, Geng L, Ma XH, et al. Severe generalized pustular psoriasis treated with mycophenolate mofetil［J］. J Dermatol, 2011,38（6）:603⁃605. doi: 10.1111/j.1346⁃8138.2010.01019.x.
［36］	Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis［J］. Expert Opin Drug Saf, 2020,19（8）:969⁃980. doi: 10.1080/14740338.2020.1785427.
［37］	Viguier M, Guigue P, Pagès C, et al. Successful treatment of generalized pustular psoriasis with the interleukin⁃1⁃receptor antagonist Anakinra: lack of correlation with IL1RN mutations［J］. Ann Intern Med, 2010,153（1）:66⁃67. doi: 10.7326/0003⁃4819⁃153⁃1⁃201007060⁃00030.
［38］	Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin⁃36 pathway for the treatment of generalized pustular psoriasis［J］. N Engl J Med, 2019,380（10）:981⁃983. doi: 10. 1056/NEJMc1811317.
［39］	Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double⁃blind, placebo⁃controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare［J］. BMJ Open, 2021,11（3）:e043666. doi: 10.1136/bmjopen⁃2020⁃043666.
［40］	Hervé Bachelez, Siew⁃Eng Choon, Slaheddine Marrakchi, et al. Trial of spesolimab for generalized pustular psoriasis［J］. N Engl J Med, 2021,385（26）:2431⁃2440. doi: 10.1056/NEJMoa2111563.
［41］	Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real⁃life experience［J］. Ther Adv Chronic Dis, 2018,9（8）:147⁃158. doi: 10.1177/2040622318772705.
［42］	Kurizky PS, Ferreira Cde C, Nogueira LS, et al. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding［J］. An Bras Dermatol, 2015,90（3）:367⁃375. doi: 10.1590/abd1806⁃4841.20153113.
［43］	Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients［J］. Joint Bone Spine, 2016,83（3）:341⁃343. doi: 10.1016/j.jbspin.2015.07.004.
［44］	Eworuke E, Panucci G, Goulding M, et al. Use of tumor necrosis factor⁃alpha inhibitors during pregnancy among women who delivered live born infants［J］. Pharmacoepidemiol Drug Saf, 2019,28（3）:296⁃304. doi: 10.1002/pds.4695.
［45］	Posso⁃De Los Rios CJ, Pope E, Lara⁃Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics［J］. Pediatr Dermatol, 2014,31（4）:430⁃439. doi: 10. 1111/pde.12351.
［46］	Eisert L, Augustin M, Bach S, et al. S2k guidelines for the treatment of psoriasis in children and adolescents ⁃ Short version part 2［J］. J Dtsch Dermatol Ges, 2019,17（9）:959⁃973. doi: 10.1111/ddg.13936.
［47］	Eisert L, Augustin M, Bach S, et al. S2k guidelines for the treatment of psoriasis in children and adolescents ⁃ Short version part 1［J］. J Dtsch Dermatol Ges, 2019,17（8）:856⁃870. doi: 10.1111/ddg.13907.
［48］	Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis［J］. Expert Rev Clin Immunol, 2019,15（9）:907⁃919. doi: 10.1080/1744666X.2019.1648209.
［49］	Bachelez H. Pustular psoriasis: the dawn of a New Era［J］. Acta Derm Venereol, 2020,100（3）:adv00034. doi: 10.2340/00015555⁃3388.
［50］	Liao PB, Rubinson R, Howard R, et al. Annular pustular psoriasis⁃⁃most common form of pustular psoriasis in children: report of three cases and review of the literature［J］. Pediatr Dermatol, 2002,19（1）:19⁃25. doi: 10.1046/j.1525⁃1470.2002. 00026.x.
［51］	Brunasso A, Massone C. Recent advances in palmoplantar pustulosis［J］. Fac Rev, 2021,10:62. doi: 10.12703/r/10⁃62.
［52］	Kromer C, Loewe E, Schaarschmidt ML, et al. Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients［J］. J Dermatol, 2020,47（9）:989⁃997. doi: 10.1111/1346⁃8138. 15466.

[1]	Sun Xiaojie, Liu Yi. Anti-androgen drugs in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2023, 56(9): 882-885.
[2]	Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 885-888.
[3]	Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848.
[4]	Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844.
[5]	Yuan Xingang, Ni Sili, Zhang Jian, Luo Xiaoyan, Wang Hua. Improving diagnosis and treatment of melanocytic nevi in children: an urgent need [J]. Chinese Journal of Dermatology, 2023, 56(8): 782-786.
[6]	Zhong Jiemin, Shao Lei, Liang Yimin, Huang Qiongxiao, Xia Manqi, Liu Yumei. Comparative study on efficacy and safety of single microneedle radiofrequency versus photodynamic therapy in the treatment of inflammatory lesions of moderate to severe facial acne vulgaris [J]. Chinese Journal of Dermatology, 2023, 56(8): 751-755.
[7]	China Dermatologist Association. Guidance on application of moisturizers and emollients: an expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(8): 711-717.
[8]	Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.
[9]	Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802.
[10]	Li Yue, Wu Jinyan, Yuan Ruoyue, Yang Quyang, Zhao Xiansheng, Zhu Ningwen. Cell therapy for hereditary epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2023, 56(7): 698-702.
[11]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.
[12]	Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650.
[13]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[14]	Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705.
[15]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.

Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［52］

Related Articles 15

Metrics

Comments

Recommended 10